Stay updated with breaking news from Specific Health Problem. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 -- Reneo...
The STRIDE study did not meet its primary or secondary efficacy endpoint
Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 -- Reneo Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the...
The efficacy and safety of low-sodium oxybate remained stable or improved over 6 months in patients with idiopathic hypersomnia.
Poor quality of life and impaired functioning across many symptom domains were shown in participants in the Real World Idiopathic Hypersomnia Outcomes Study (ARISE).